Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Bulletin from Simris Group AB’s Extraordinary General Meeting

Simris Group
Download the release

Simris Group AB (publ), reg. no. 556841–9187 (the "Company") held an extraordinary general meeting on 20 January 2025. Below follows a summary of the resolutions that were passed at the meeting.

Resolution on entering into loan agreements
The general meeting resolved to enter into loan agreements with Frank Puccio amounting to EUR 50,000, Royce CoLabs AB, a company controlled by Jonathan Royce, amounting to EUR 10,000, Magnus Högström amounting to EUR 30,000, Arminnovate Ltd, a company controlled by Dr Alexis Roberts-McIntosh, Amounting to EUR 20,000 and Christoffer Tell AB, a company controlled by Christoffer Tell amounting to EUR 30,000 for a total loan amount of EUR 140,000 and to instruct the board of directors to execute the loan agreements (“Loan Agreements”).
 
The Loan Agreements shall have a monthly interest rate of one (1) per cent and a maturity date of 31 December 2025. The lenders shall have a right to convert all outstanding loan and interest to B-shares at a subscription price of SEK 0.05 per B-share. If the Company conducts a capital raise before 31 December 2025 the subscription price shall be lowered to correspond with the subscription price in such capital raise.
 
The board of directors submitted the Loan Agreements to the general meeting for approval due to conflict of interests of its members according to the Swedish Companies Act.

Contact Details:
Dr Alexis Roberts-McIntosh
CEO Simris Group AB
Email: ir@simris.com
Mobile: +44 (0) 7940 585298
www.simrisgroup.com

About Simris Group AB (PUBL):
Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics. 

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

Attachments
Bulletin from Simris Group AB’s Extraordinary General Meeting

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.